Antimicrobial resistance (AMR) is a global health challenge with an estimated 67% increase in global deaths attributable to AMR by 2050. The European Partnership One Health AMR (EUP OHAMR) is aiming to reduce the burden of AMR with an integrated One Health (OH) approach, recognising that human, animal and plant health are interdependent and interlinked with the environment. The partnership will boost AMR research and innovation (R&I) addressing the current knowledge gaps with the aim to improve surveillance of resistant pathogens and provide better diagnostics and more effective treatments of drug-resistant infections. It will support implementation research on prevention measures reducing the use of antimicrobials and spread of AMR and launch an ambitious work programme of joint activities to coordinate R&I investments, facilitate the use and re-use of R&I data, strengthen AMR R&I capacities and facilitate both knowledge translation and uptake of research results and innovations by industry, society, and policy makers. The EUP OHAMR builds on the long-standing collaboration of the partners from the Joint Programme Initiative on AMR (JPIAMR) but with a bigger ambition and a broader scope. The partnership consists of 53 partners from 30 countries from the European Union (EU) and beyond. With active engagement of key stakeholders across the AMR landscape, the partnership will strengthen European and global synergies through alignment of research priorities, policies, and investments. Furthermore, EUP OHAMR will support multisectoral and multidisciplinary collaborations to break the existing silos in AMR research. It will result in increased knowledge and solutions and provide an evidence base for uptake into policy and practice to prevent and tackle AMR. Thus, the EUP OHAMR will deliver towards to the priorities set in the European One Health Action plan against AMR, thereby strengthening the European Research and Innovation Area ecosystem and contribute to making the EU a best-practice region on AMR.